Hikma Ventures
VC Fund
London, United Kingdom
Hikma Ventures is a VC fund in London focused on Health Care and Medical. HV will act as an instrument of strategic growth in broadening Hikma’s offerings; it will allow Hikma to tap into opportunities in the growing digital health space.HV will invest in companies where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinationalpharmaceutical company.We will invest in companies at all stages of development, including start-ups, spinouts, and consortia investments.Our initial investment size is up to $5 million per round. HV will look at global opportunities but with a focus on the US and the Middle East & Africa (MEA).We seek to actively partner with the management teams of portfolio companies to realize the potential of their products and technologies.
- Total investments:
- 28
- Last investment:
- Lead investor:
- 29%
- Fund size:
- $30M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Hikma Ventures invests in
Stages Hikma Ventures invests in
Countries Hikma Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Series A
- $4.2M–$14M
- Series B
- $15M–$100M
- Series C
- $21M–$100M
Investment Focus
Industry
- Health Care 14 (50%)
- Medical 7 (25%)
- Biotechnology 6 (21%)
- Medical Device 6 (21%)
- Artificial Intelligence 4 (14%)
Stage
- Series A 9 (32%)
- Series B 7 (25%)
- Series C 4 (14%)
- Seed 3 (11%)
- Series D 1 (4%)
Country
- United States 13 (46%)
- Canada 2 (7%)
- Egypt 1 (4%)
- United Arab Emirates 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Lana Ghanem
Founder & Managing Director
|
Founder & Managing Director | Total investments: 14 | Find email | |
|
Ahmad Fayyad
Associate
|
Associate | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Octave
|
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $35.6M / Series C / Sep 04, 2025 | |
Biolinq
|
Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M / Series C / Mar 19, 2025 | |
|
Octave
|
Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $30M / Series B / Jul 26, 2023 | |
Prognos Health
|
Prognos Health is a leading health tech company that is pushing the boundaries of healthcare analytics. The company’s platform, prognosFACTOR, has the power to query billions of lab and health records on more than 325 million de-identified patients to answer clinically-focused healthcare questions in minutes, not months. The platform enables thequerying and purchasing of patient-centric, HIPAA-Compliant healthcare data from the Prognos Marketplace to address diverse applications, including cohort design, patient journey studies, health outcomes and more. Customers include 25 of the top 30 pharmaceutical manufacturers and three of the top five payers. | $23.3M / May 04, 2023 | |
O7 Therapy
|
O7 Therapy is revolutionizing access to mental health services through a digital platform and mobile app offering online therapy, psycho-educational resources, and corporate wellness programs, to empower Arabic-speaking people to pursue their mental wellness journey. We use cutting edge AI in a very engaging user experience producing an effectivetherapeutic journey. Additionally, we provide Employee Wellness Programs for organizations through a unique B2B2E model, prioritizing the impact of mental health challenges in the workplace, and focusing on raising awareness and understanding, reducing stigma and shame, creating safe and supportive spaces, and implementing strategies that promote mental wellbeing. | $2.1M / Seed / Apr 03, 2022 | |
Altoida
|
Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet.Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR),and artificial intelligence (AI).Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt. | $14M / Series A / Mar 30, 2022 | |
Altibbi
|
Altibbi is a digital health platform that offers tools and information to provide access to health advice 24/7 anywhere through its website and apps. | $44M / Series B / Mar 28, 2022 | |
Activ Surgical
|
Activ Surgical is a digital surgery company focused on improving surgical efficiency, accuracy, patient outcomes, and accessibility. Its scalable and patent-protected surgical software platform technology is driven by computer vision, artificial intelligence, analytics, and machine learning to enhance a surgeon’s intra-operative decision making,and reduce unintended and preventable surgical complications.The company was founded in 2017 and is headquartered in Boston, Massachusetts. | $15M / Series B / Mar 22, 2022 | |
NuvoAir
|
NuvoAir Medical is a value-based specialty management platform transforming the diagnosis and management of chronic heart and lung conditions. NuvoAir’s care model integrates advanced monitoring technology and analytics with evidence-based interventions, all delivered by a multidisciplinary team. This approach ensures that each patient'sjourney is highly personalized. Collaborating with health plans and risk-bearing entities through flexible, value-based payment arrangements, NuvoAir distinguishes itself as a specialty care provider, effectively reducing healthcare costs and enhancing overall outcomes. | $11M / Series A / Jan 19, 2022 | |
|
NuvoAir
|
NuvoAir Medical is a value-based specialty management platform transforming the diagnosis and management of chronic heart and lung conditions. NuvoAir’s care model integrates advanced monitoring technology and analytics with evidence-based interventions, all delivered by a multidisciplinary team. This approach ensures that each patient'sjourney is highly personalized. Collaborating with health plans and risk-bearing entities through flexible, value-based payment arrangements, NuvoAir distinguishes itself as a specialty care provider, effectively reducing healthcare costs and enhancing overall outcomes. | $11M / Series A / Jan 19, 2022 | |
| See all 28 investments → | |||
Co-Investors
M Ventures
5 deals together
Safeguard Scientifics
4 deals together
Aphelion Capital
3 deals together
Civilization Ventures
3 deals together
LifeSci Venture Partners
3 deals together
Merck Global Health Innovation Fund
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Hikma Ventures invest in?
Hikma Ventures invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Hikma Ventures's check size?
Hikma Ventures typically joins rounds of $4.2M–$14M at Series A, $15M–$100M at Series B and $21M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Hikma Ventures participates in.
How do I contact Hikma Ventures?
Public channels for Hikma Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Hikma Ventures?
The team at Hikma Ventures includes Lana Ghanem (Founder & Managing Director) and Ahmad Fayyad (Associate). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
